Market closedADR
Bicycle Therapeutics/$BCYC
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Bicycle Therapeutics
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
Ticker
$BCYC
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
284
Website
BCYC Metrics
BasicAdvanced
$1B
Market cap
-
P/E ratio
-$3.23
EPS
0.89
Beta
-
Dividend rate
Price and volume
Market cap
$1B
Beta
0.89
52-week high
$27.24
52-week low
$12.17
Average daily volume
741K
Financial strength
Current ratio
17.13
Quick ratio
16.822
Long term debt to equity
0.666
Total debt to equity
1.334
Interest coverage (TTM)
-78.64%
Management effectiveness
Return on assets (TTM)
-15.01%
Return on equity (TTM)
-26.67%
Valuation
Price to revenue (TTM)
20.956
Price to book
1.25
Price to tangible book (TTM)
1.25
Price to free cash flow (TTM)
-3.799
Growth
Revenue change (TTM)
48.60%
Earnings per share change (TTM)
-35.25%
3-year revenue growth (CAGR)
46.34%
3-year earnings per share growth (CAGR)
3.98%
What the Analysts think about BCYC
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Bicycle Therapeutics stock.
BCYC Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
BCYC Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
BCYC News
AllArticlesVideos
Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification
Business Wire·1 week ago
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·3 weeks ago
Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Bicycle Therapeutics stock?
Bicycle Therapeutics (BCYC) has a market cap of $1B as of December 21, 2024.
What is the P/E ratio for Bicycle Therapeutics stock?
The price to earnings (P/E) ratio for Bicycle Therapeutics (BCYC) stock is 0 as of December 21, 2024.
Does Bicycle Therapeutics stock pay dividends?
No, Bicycle Therapeutics (BCYC) stock does not pay dividends to its shareholders as of December 21, 2024.
When is the next Bicycle Therapeutics dividend payment date?
Bicycle Therapeutics (BCYC) stock does not pay dividends to its shareholders.
What is the beta indicator for Bicycle Therapeutics?
Bicycle Therapeutics (BCYC) has a beta rating of 0.89. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.